2.110USD+0.48%Mkt Cap: 210.26M USDP/E: —Last update: 2026-05-26
Caribou Biosciences, Inc. operates as a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company. It offers a genome-editing platform based on novel CRISP…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
105.81BDKKP/E 20.4
66.47BUSDP/E 15.5
46.56BEURP/E 30.5
43.89BEURP/E 36.5
39.41BUSDP/E 74.0
32.84BUSD—
32.05BSEKP/E 47.4
Indicators:|
Key Statistics
Company
Market Cap210.26M USD
Enterprise Value106.69M USD
Revenue (TTM)11.20M USD
Gross Profit-96.32M USD
Net Income (TTM)-148.13M USD
Revenue/Share0.1190 USD
Last Price2.110 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees97
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-1.42
PEG—
EV/EBITDA-0.94
EV/Revenue9.52
P/S17.62
P/B1.89
EPS (TTM)-1.42
EPS (Forward)-1.40
52W Range
0.957045% of range3.535
52W High3.535 USD
52W Low0.9570 USD
Profitability
Gross Margin0.00%
Oper. Margin-1096.37%
EBITDA Margin0.00%
Profit Margin-1327.40%
ROE-121.24%
ROA-84.47%
Growth
Revenue Growth1.90%
Earnings Growth—
Cash Flow & Leverage
Operating CF-110.99M USD
CapEx (TTM)1.36M USD
FCF Margin-553.28%
FCF Yield-29.48%
Net Debt-90.68M USD
Net Debt/EBITDA0.79
Balance Sheet
Debt/Equity0.22
Current Ratio6.22
Quick Ratio6.10
Book Value/Sh1.052 USD
Cash/Share1.186 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.1 (Strong Buy)
Target (Mean)12.00 USD
Target Range4.000 USD – 32.00 USD
# Analysts7
Ownership
Shares Out.99.18M
Float94.77M
Insiders8.91%
Institutions37.87%
Short Interest
Short Ratio4.9d
Short % Float7.48%
Short % Out.7.18%
Shares Short7.12M
Short (prev mo.)6.47M
Technical
SMA 501.994 (+5.8%)
SMA 2001.931 (+9.3%)
Beta—
S&P 52W Chg28.31%
Avg Vol (30d)1.67M
Avg Vol (10d)1.85M
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—